Bender Robert & Associates’s Clovis Oncology CLVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-50,000
Closed -$60K – 56
2022
Q3
$60K Hold
50,000
– – 0.02% 50
2022
Q2
$90K Buy
+50,000
New +$73.8K 0.03% 51
2021
Q2
– Sell
-50,000
Closed -$351K – 57
2021
Q1
$351K Buy
+50,000
New +$335K 0.11% 47

Other funds holding CLVS

Bender Robert & Associates's CLVS Position: Q4 2022 in Review

Bender Robert & Associates sold out of Clovis Oncology (CLVS) in Q4 2022, closing a stake of 50,000 shares — an estimated $60K sold.

Bender Robert & Associates first reported a position in CLVS in Q1 2021 and held it in 3 quarters. The position peaked at $351K in Q1 2021. 14 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Bender Robert & Associates reported no remaining Clovis Oncology position as of Q4 2022 after selling out during the quarter.
  • Bender Robert & Associates sold 50,000 Clovis Oncology shares in Q4 2022, an estimated $60K.
  • Bender Robert & Associates first reported a position in Clovis Oncology in Q1 2021 and held it in 3 quarters.
  • Bender Robert & Associates's Clovis Oncology position peaked at $351K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Clovis Oncology as of Q4 2022.

Based on Bender Robert & Associates's 13F filing for Q4 2022, filed 2 Feb 2023.